JP6285469B2 - 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 - Google Patents
呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 Download PDFInfo
- Publication number
- JP6285469B2 JP6285469B2 JP2015562115A JP2015562115A JP6285469B2 JP 6285469 B2 JP6285469 B2 JP 6285469B2 JP 2015562115 A JP2015562115 A JP 2015562115A JP 2015562115 A JP2015562115 A JP 2015562115A JP 6285469 B2 JP6285469 B2 JP 6285469B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion
- flys
- gcn
- recombinant polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 title claims description 149
- 230000004927 fusion Effects 0.000 title claims description 113
- 241000725643 Respiratory syncytial virus Species 0.000 title claims description 95
- 239000000203 mixture Substances 0.000 title claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 107
- 229920001184 polypeptide Polymers 0.000 claims description 85
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 85
- 238000003776 cleavage reaction Methods 0.000 claims description 47
- 230000007017 scission Effects 0.000 claims description 47
- 102000004961 Furin Human genes 0.000 claims description 32
- 108090001126 Furin Proteins 0.000 claims description 32
- 238000005829 trimerization reaction Methods 0.000 claims description 29
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims description 26
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims description 26
- 229960005486 vaccine Drugs 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 22
- 230000002163 immunogen Effects 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 230000000890 antigenic effect Effects 0.000 claims description 13
- 239000013604 expression vector Substances 0.000 claims description 13
- 239000013638 trimer Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010013639 Peptidoglycan Proteins 0.000 claims description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 5
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000003660 reticulum Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 95
- 102000004169 proteins and genes Human genes 0.000 description 90
- 235000018102 proteins Nutrition 0.000 description 89
- 230000009257 reactivity Effects 0.000 description 40
- 102000004142 Trypsin Human genes 0.000 description 28
- 108090000631 Trypsin Proteins 0.000 description 28
- 239000012588 trypsin Substances 0.000 description 28
- 230000003472 neutralizing effect Effects 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 229960000402 palivizumab Drugs 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 19
- 241000711920 Human orthopneumovirus Species 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
- 235000004279 alanine Nutrition 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 238000012286 ELISA Assay Methods 0.000 description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 13
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 235000018417 cysteine Nutrition 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 229920002873 Polyethylenimine Polymers 0.000 description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 210000005220 cytoplasmic tail Anatomy 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 229940036185 synagis Drugs 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 108091006027 G proteins Proteins 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000711895 Bovine orthopneumovirus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000011537 Coomassie blue staining Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 241000342334 Human metapneumovirus Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 102400001093 PAK-2p27 Human genes 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108091000126 Dihydroorotase Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 102000008826 LysM domains Human genes 0.000 description 1
- 108050000721 LysM domains Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- -1 NadA Proteins 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000053391 human F Human genes 0.000 description 1
- 108700031895 human F Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 101800002712 p27 Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/828,667 | 2013-03-14 | ||
| US13/828,667 US9060975B2 (en) | 2013-03-14 | 2013-03-14 | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| PCT/EP2014/054804 WO2014140083A1 (en) | 2013-03-14 | 2014-03-12 | Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510983A JP2016510983A (ja) | 2016-04-14 |
| JP2016510983A5 JP2016510983A5 (https=) | 2017-02-23 |
| JP6285469B2 true JP6285469B2 (ja) | 2018-02-28 |
Family
ID=50241453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562115A Expired - Fee Related JP6285469B2 (ja) | 2013-03-14 | 2014-03-12 | 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9060975B2 (https=) |
| EP (2) | EP3178840A1 (https=) |
| JP (1) | JP6285469B2 (https=) |
| CN (2) | CN107029227A (https=) |
| AU (1) | AU2014230822B2 (https=) |
| BR (1) | BR112015022617A2 (https=) |
| CA (1) | CA2905571A1 (https=) |
| WO (1) | WO2014140083A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2900110A1 (en) | 2013-02-01 | 2014-08-07 | Medimmune, Llc | Respiratory syncytial virus f protein epitopes |
| EP3798310A1 (en) | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| MX2018005462A (es) | 2015-10-29 | 2018-08-01 | Univ Emory | Composiciones inmunogénicas de rsv quimérico y métodos de uso. |
| IL262108B2 (en) * | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| CN109311946A (zh) * | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| CN108300705B (zh) * | 2017-01-12 | 2021-10-22 | 厦门大学 | 稳定呼吸道合胞病毒融合蛋白的方法 |
| KR20260047644A (ko) | 2017-03-30 | 2026-04-08 | 더 유니버서티 어브 퀸슬랜드 | 키메라 분자 및 그의 용도 |
| HUE073526T2 (hu) | 2017-04-04 | 2026-01-28 | Univ Washington | Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata |
| WO2019063844A1 (en) * | 2017-09-29 | 2019-04-04 | Universiteit Antwerpen | VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS |
| BR112020015308A8 (pt) * | 2018-01-29 | 2023-02-07 | Merck Sharp & Dohme | Proteínas f de rsv estabilizadas e usos das mesmas |
| CN110684747B (zh) * | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| KR102725189B1 (ko) * | 2018-11-01 | 2024-10-31 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
| CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
| CN114957407A (zh) * | 2019-04-02 | 2022-08-30 | 赛诺菲 | 抗原性多聚呼吸道合胞病毒多肽 |
| CN110054668B (zh) * | 2019-04-25 | 2021-09-10 | 北京交通大学 | 一种呼吸道合胞病毒融合前f蛋白及其应用 |
| EP4025587A1 (en) | 2019-09-04 | 2022-07-13 | University of Washington | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use |
| CN111303245B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
| JP7627447B2 (ja) * | 2020-04-22 | 2025-02-06 | ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション | 三量体を形成するインフルエンザウイルス表面タンパク質由来組換え赤血球凝集素タンパク質およびその用途 |
| WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
| CN112480217B (zh) * | 2020-11-30 | 2022-04-08 | 广州阿格纳生物医药制造有限公司 | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 |
| KR20250140099A (ko) * | 2023-02-03 | 2025-09-24 | 노바백스, 인코포레이티드 | Rsv f 백신 제형 |
| WO2024192698A1 (zh) * | 2023-03-22 | 2024-09-26 | 中科牧维(南京)生物科技有限公司 | 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂 |
| CN121464149A (zh) * | 2023-06-07 | 2026-02-03 | 四川三叶草生物制药有限公司 | Rsv疫苗组合物、方法及其用途 |
| US12383614B2 (en) | 2023-12-21 | 2025-08-12 | Yikang Biotech (Suzhou) Co., Ltd. | Mutants of respiratory syncytial virus fusion proteins |
| CN117886902B (zh) * | 2023-12-21 | 2024-11-26 | 易康生物(苏州)有限公司 | 改良的呼吸道合胞病毒融合f蛋白突变体及其应用 |
| CN121221752A (zh) * | 2025-02-14 | 2025-12-30 | 北京悦康科创医药科技股份有限公司 | 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用 |
| CN120329390A (zh) * | 2025-03-03 | 2025-07-18 | 中国医学科学院医学生物学研究所 | 基于异源三聚体基序的蛋白的改造及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0916726A1 (en) | 1997-11-13 | 1999-05-19 | Rijksuniversiteit te Groningen | Attaching substances to micro-organisms |
| DK1395648T3 (da) | 2001-06-11 | 2009-08-03 | Applied Nanosystems Bv | Fremgangsmåder til binding af AcmA-type proteinankerfusioner til cellevægsmateriale af mikroorganismer |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| EP2445527A2 (en) | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
| HUE028085T2 (en) | 2009-06-24 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Recombinant RSV antigens |
| CA2768186A1 (en) * | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| US9585953B2 (en) | 2011-03-22 | 2017-03-07 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
| CA2835644C (en) | 2011-05-13 | 2021-06-15 | Novartis Ag | Pre-fusion rsv f antigens |
-
2013
- 2013-03-14 US US13/828,667 patent/US9060975B2/en not_active Ceased
-
2014
- 2014-03-12 BR BR112015022617A patent/BR112015022617A2/pt not_active IP Right Cessation
- 2014-03-12 CN CN201710040168.9A patent/CN107029227A/zh active Pending
- 2014-03-12 WO PCT/EP2014/054804 patent/WO2014140083A1/en not_active Ceased
- 2014-03-12 CA CA2905571A patent/CA2905571A1/en not_active Abandoned
- 2014-03-12 JP JP2015562115A patent/JP6285469B2/ja not_active Expired - Fee Related
- 2014-03-12 CN CN201480022815.8A patent/CN105246910A/zh active Pending
- 2014-03-12 EP EP16200916.1A patent/EP3178840A1/en not_active Withdrawn
- 2014-03-12 EP EP14709318.1A patent/EP2970393B1/en not_active Not-in-force
- 2014-03-12 AU AU2014230822A patent/AU2014230822B2/en not_active Ceased
-
2016
- 2016-03-26 US US15/081,854 patent/USRE47471E1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107029227A (zh) | 2017-08-11 |
| EP3178840A1 (en) | 2017-06-14 |
| CN105246910A (zh) | 2016-01-13 |
| AU2014230822A1 (en) | 2015-10-01 |
| US9060975B2 (en) | 2015-06-23 |
| USRE47471E1 (en) | 2019-07-02 |
| CA2905571A1 (en) | 2014-09-18 |
| AU2014230822B2 (en) | 2018-04-12 |
| EP2970393A1 (en) | 2016-01-20 |
| US20140271696A1 (en) | 2014-09-18 |
| WO2014140083A1 (en) | 2014-09-18 |
| JP2016510983A (ja) | 2016-04-14 |
| BR112015022617A2 (pt) | 2017-10-31 |
| EP2970393B1 (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6285469B2 (ja) | 呼吸器合胞体ウイルスの熱安定な融合前ｆタンパク質オリゴマーおよび免疫組成物におけるその使用 | |
| Rigter et al. | A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles | |
| CN101952321B (zh) | 重组rsv抗原 | |
| DK2445526T3 (en) | Recombinant RSV antigens. | |
| JP7094103B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| CN103547676B (zh) | 颗粒形式的免疫原性组合物和用于产生其的方法 | |
| CN102548578A (zh) | 疫苗 | |
| CN116096407A (zh) | 重组人偏肺病毒f蛋白及其用途 | |
| US20160122398A1 (en) | Recombinant rsv antigens | |
| Widjaja et al. | Recombinant soluble respiratory syncytial virus F protein that lacks heptad repeat B, contains a GCN4 trimerization motif and is not cleaved displays prefusion-like characteristics | |
| CN121620537A (zh) | Rsv和hmpv融合f蛋白及其用途 | |
| Rigter et al. | A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170117 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180201 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6285469 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |